Literature DB >> 27349979

Immune checkpoint inhibitors side effects and management.

Hampig Raphael Kourie1, Jean Klastersky1.   

Abstract

The next decade in cancer therapy will be marked by the expansion of immunotherapies, namely immune checkpoint inhibitors. The increasing number and combination of checkpoint inhibitors and the variety of their mechanisms of action and indications will most likely multiply the side effects associated with these therapies and make their management more complicated and diversified. Given the growing rate of approval of different checkpoint inhibitors in different cancers in multiple settings, a review summarizing the major side effects of the new agents in use today and their management seems to be appropriate. Highlighting these adverse events and their management in a single review might help the daily practice of the physicians and consequently contribute the patient's safety and quality of life.

Entities:  

Keywords:  checkpoint inhibitors; immunotherapy; side effects

Mesh:

Substances:

Year:  2016        PMID: 27349979     DOI: 10.2217/imt-2016-0029

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  18 in total

Review 1.  [Adverse effects of immunotherapy : Clinical aspects, radiological and nuclear medicine results].

Authors:  G Widmann; V A Nguyen; J Plaickner; W Jaschke
Journal:  Radiologe       Date:  2017-10       Impact factor: 0.635

2.  Supportive care for patients undergoing immunotherapy.

Authors:  Bernardo Leon Rapoport; Ronwyn van Eeden; Vincent Sibaud; Joel B Epstein; Jean Klastersky; Matti Aapro; Devan Moodley
Journal:  Support Care Cancer       Date:  2017-07-13       Impact factor: 3.603

Review 3.  Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy.

Authors:  Sigrun Smola; Connie Trimble; Peter L Stern
Journal:  Ther Adv Vaccines       Date:  2017-07-05

Review 4.  Targeting PVR (CD155) and its receptors in anti-tumor therapy.

Authors:  Paola Kučan Brlić; Tihana Lenac Roviš; Guy Cinamon; Pini Tsukerman; Ofer Mandelboim; Stipan Jonjić
Journal:  Cell Mol Immunol       Date:  2018-10-01       Impact factor: 11.530

5.  Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy.

Authors:  Samer Tabchi; Hampig Raphael Kourie; Joseph Kattan
Journal:  Invest New Drugs       Date:  2016-08-25       Impact factor: 3.850

6.  In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.

Authors:  Stefan Grote; Guillermo Ureña-Bailén; Kenneth Chun-Ho Chan; Caroline Baden; Markus Mezger; Rupert Handgretinger; Sabine Schleicher
Journal:  Cells       Date:  2021-04-26       Impact factor: 6.600

Review 7.  Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy.

Authors:  Gerlig Widmann; Van Anh Nguyen; Julian Plaickner; Werner Jaschke
Journal:  Curr Radiol Rep       Date:  2017-09-11

8.  Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells.

Authors:  Mohammad Rashidian; Jessica R Ingram; Michael Dougan; Anushka Dongre; Katherine A Whang; Camille LeGall; Juan J Cragnolini; Brian Bierie; Monica Gostissa; James Gorman; Gijsbert M Grotenbreg; Atul Bhan; Robert A Weinberg; Hidde L Ploegh
Journal:  J Exp Med       Date:  2017-06-30       Impact factor: 14.307

Review 9.  Immune Checkpoint in Glioblastoma: Promising and Challenging.

Authors:  Jing Huang; Fangkun Liu; Zhixiong Liu; Hui Tang; Haishan Wu; Qianni Gong; Jindong Chen
Journal:  Front Pharmacol       Date:  2017-05-09       Impact factor: 5.810

10.  Marshallagia marshalli Antigen Strengthens Dendritic Cell Mediated T Lymphocyte Regulation on Asthmatic Patients.

Authors:  Fatemeh Hemati; Majid Mirsadraei; Milad Hemati; Hadi Mohebalian; Hassan Borji
Journal:  Iran J Parasitol       Date:  2020 Jan-Mar       Impact factor: 1.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.